ArticleCancers2021

No Impact of NRAS Mutation on Features of Primary and Metastatic Melanoma or on Outcomes of Checkpoint Inhibitor Immunotherapy: An Italian Melanoma Intergroup (IMI) Study.

Michele Guida et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.